Owner's Guides

Veterinary Practices for Sale: Selling and Valuing a Vet Practice

How US veterinary practice sales and valuations actually work today, with real multiples, named buyers, deal structures, process, and pitfalls.

Palmstone Capital Research10 min read

Corporate groups need what you built.

If you own a veterinary practice, you are sitting on two different assets depending on who buys it. Sell to another DVM and you're pricing an income stream a single working owner will personally replace. Sell to a corporate platform and you're pricing transferable cash flow after a market-rate veterinarian is already paid out of the numbers. Mixing the two up, or applying a headline multiple you read online without knowing which one it belongs to, is where most owners lose money before they even reach an LOI.

This page walks through the decision an owner actually faces: retire and exit cleanly, sell to an associate, or sell into a consolidator with some form of ongoing involvement. Each path has a different buyer pool, a different valuation basis, and a different cash-at-close reality.

Your three real options

Full exit to an independent buyer. Usually an existing associate, a nearby practice owner, or a first-time DVM buyer using SBA or bank financing. This path is more likely to preserve local ownership and culture, but the buyer's purchasing power is capped by what a lender will underwrite against the practice's cash flow. Pricing here runs off seller's discretionary earnings (SDE), not EBITDA. Current US listings show a 2.74x to 4.13x SDE asking range, median 3.44x, and a 0.75x to 1.20x revenue range, median 1.00x, based on 51 live listings with reported financials on BizBuySell. These are asking prices, not closed-sale data.

Full or majority sale to a corporate platform. This is the route for practices with multiple doctors, durable EBITDA, and limited owner concentration. Pricing runs off normalized EBITDA after a market veterinarian wage is charged against the owner's own clinical production. The current corporate range is roughly 8x to 15x EBITDA, with exceptional multi-doctor assets reaching 16x or better. This is not one number: a two-to-three-DVM practice with modest EBITDA prices very differently from a four-plus-DVM hospital with strong margin and growth.

Partial sale or hospital-level joint venture. Some platforms, notably NVA, let a seller take liquidity now while retaining hospital-level or parent-company equity and staying clinically or operationally involved. The headline multiple on this structure can look higher than an all-cash deal, but the retained piece is illiquid and its value depends on future EBITDA growth, waterfall terms, and the platform's own eventual exit. Treat it as a bet on the platform, not as cash in hand.

Who is actually buying

Buyer category	Named examples	What they target
Global strategic networks	Mars Veterinary Health (VCA, Banfield, BluePearl); VCA alone runs 1,000+ hospitals across the US, Canada and Japan	Scale GP, specialty and emergency; deep clinical and back-office infrastructure
National corporate consolidators	NVA and Ethos Veterinary Health, roughly 1,300 North American locations plus 140+ Ethos specialty/ER sites	GP, specialty, ER, equine, pet resorts; hospital-level JV participation offered
Large PE-backed platforms	Mission Pet Health (formed from Southern Veterinary Partners and Mission Veterinary Partners, an $8.6 billion recapitalization involving 750+ facilities); Vetcor; PetVet Care Centers, 420+ hospitals; CareVet, 200+ hospitals	Multi-DVM GP and mixed GP/specialty groups; local brand retained, back office centralized
Regional and mid-market platforms	Alliance Animal Health, 250+ practices in 29 states; Encore Vet Group; Blue River PetCare; plus Heartland Veterinary Partners, Community Veterinary Partners, Veterinary Practice Partners, Rarebreed Veterinary Partners, AmeriVet	Two-to-four-DVM hospitals, regional density, often more flexible on size than the national names
Local DVM or associate	Existing associate, nearby independent owner, first-time buyer	SBA or bank-financed full acquisition; capped by lender underwriting

None of these buyers publish price cards. The ranges above are market estimates drawn from advisor-reported completed deals, not offer commitments.

Valuation, size tier by size tier

Practice profile	Basis	Current range
Solo or heavily owner-produced GP, roughly $0.8M-$1.35M revenue	Asking price / SDE	2.74x-4.13x SDE, median 3.44x
Two to three DVM GP, normalized EBITDA roughly $250K-$700K	Enterprise value / EBITDA	8x-11x, estimate
Four or more DVM GP, $700K+ EBITDA, strong growth	Enterprise value / EBITDA	11x-14x typical, 13.5x-16x for top performers
Multi-site regional group, $1.5M+ EBITDA	Enterprise value / EBITDA	12x-16x, above 16x possible for strategic density
Specialty or emergency hospital	Enterprise value / EBITDA	8x-14x, wide range driven by key-person risk

Ackerman Group, a specialist sell-side advisor, reported a 13.4x weighted-average GP EBITDA multiple in H1 2026, up from 12.4x in H2 2025. That average is pulled upward by a small number of large, highly profitable hospitals. Multiples for most other practices have been flat for more than two years, so do not apply a 13x headline to a solo or two-doctor clinic.

A quick worked example. Say your practice reports $650,000 EBITDA on paper. A corporate buyer adds back $60,000 in personal and nonrecurring expenses, then subtracts $200,000 for a market replacement veterinarian in place of your own clinical production, and another $40,000 to move a below-market lease to a market rent. Normalized EBITDA comes to $470,000. At a 10x multiple for a mid-size GP, enterprise value is $4.7 million. Cash at close, at the current 65% average, is roughly $3.05 million, before debt payoff, transaction fees and tax. The number on the LOI and the number in your account are not the same number.

The associate-shortage effect on value

The single biggest swing factor in a corporate valuation right now is whether your associates will still be there after closing. Buyers underwrite value assuming the current doctor team stays, and a practice where one associate is essential and unsigned, or where a doctor has recently left, gets priced down or pushed toward a heavier earnout. Ackerman's 2025 data shows retention incentives averaging over $140,000 per associate for practices with one to three associates, an expense buyers now build into nearly every corporate deal. On the flip side, four or more productive doctors with no single clinician holding a critical share of revenue is one of the strongest upward factors on the multiple. If you are the practice's main producer and plan to retire at closing, expect that to show up as a lower multiple or a longer required transition, not just a smaller number on the same multiple.

Deal structures

Corporate transactions commonly pay 40% to 80% cash at closing, averaging around 65%. The balance shows up as an earnout, a contingent seller note, hospital-level JV interest, or retained parent-company equity. Most deals are asset purchases, cash-free and debt-free, with real estate handled separately, either retained by the seller and leased to the buyer at market rent, or sold in its own transaction. When comparing two offers, look past the headline multiple to cash at close, how the earnout is measured and controlled, rollover security and liquidation preference, post-close employment compensation, the working-capital adjustment, and how the price is allocated for tax.

Ownership rules vary sharply by state. Texas restricts veterinary practice ownership to Texas-licensed veterinarians under Occupations Code Section 801.506. California requires premises registration to be updated within 30 days of an ownership change under Business and Professions Code Section 4853. New York licenses veterinary medicine under Education Law Article 135 with its own professional-entity rules. Where a non-veterinarian buyer wants in, deals in restricted states are commonly structured as a veterinarian-owned professional entity paired with a management services organization that owns the nonclinical assets, so long as the arrangement does not transfer clinical control.

Process and timeline

A competitive corporate sale typically runs 5 to 7 months from engagement to close. Mission Pet Health, for example, states 30 to 45 days for valuation and 90 to 120 days from decision to close. An associate or lender-financed sale usually takes longer, roughly 6 to 12 months, especially where SBA underwriting, seller financing, or real estate negotiations are involved.

Readiness (6-24 months out). Stabilize the DVM team, clean up PIMS and financial records, resolve any board, DEA, wage or lease issues, and decide what happens with real estate.
Data collection (2-4 weeks). Three years of tax returns and monthly P&L, production by DVM, payroll, invoice and active-client counts, leases, and permits.
Valuation and marketing (2-4 weeks). Normalized EBITDA, buyer list, teaser and confidential information memorandum.
Buyer outreach (4-6 weeks). NDAs, indications of interest, management meetings. A competitive process with multiple bidders is itself a value driver.
LOI and negotiation (1-3 weeks). Compare structures, not just headline price.
Confirmatory diligence (8-14 weeks). Quality of earnings, legal, HR, clinical compliance, controlled substances, and facility review.
Permits and transition (3-8 weeks, overlapping). Landlord and lender consent, new clinical entity documents if needed, DEA and state drug registration transfer, x-ray registration.
Staff communication (final 3-4 weeks). Associate retention offers typically go out about a week before the general staff announcement.
Closing (1-3 days). Funds flow, debt payoff, escrow, inventory count, permit effectiveness.

Pitfalls that kill deals or destroy value

Using gross revenue as your only valuation method. A 1.0x revenue asking median for small listings does not translate to a corporate EBITDA multiple and ignores owner replacement cost entirely.
Not charging yourself a market DVM wage in your own numbers. This overstates transferable EBITDA and collapses value late, once quality-of-earnings work catches the missing labor cost.
Letting an associate walk, or telling too many people too early. Nearly every corporate deal now includes associate retention packages for this exact reason.
Treating a 13x headline offer as 13x in cash. At a 65% average cash-at-close, that offer is closer to 8.5x in your account on day one.
Letting invoice count or active clients slide during the 5-to-7-month process. Buyers can retrade price or shift more consideration into contingent structures if trailing performance falls during diligence.
Ignoring the lease until the LOI stage. A short remaining term, a nonassignable lease, or below-market rent that has to reset to market can quietly cut EBITDA and buyer interest.
Assuming licenses transfer automatically. DEA registration, state drug registration, x-ray registration and the premises permit all require separate handling. Closing without effective authority in place can stop clinical operations on day one.

FAQ

What is my veterinary practice worth?

Start with SDE if you expect an owner-operator buyer, or normalized EBITDA if you expect a corporate buyer. Apply a size- and buyer-appropriate multiple, then separate that enterprise value from real estate, debt, deferred consideration, fees and tax to get to what actually lands in your account.

Is one times gross revenue still a valid rule of thumb?

It's a rough cross-check for small practices at best. Current listings show a 1.00x median asking multiple with a 0.75x to 1.20x range, but profitability, doctor coverage and owner dependence are what actually set the price.

Why is my corporate EBITDA lower than the profit on my tax return?

A buyer subtracts market compensation for your own clinical production and normalizes rent, benefits and recurring costs. Personal expenses and genuine one-time costs may be added back, but your own uncompensated labor and below-market rent get subtracted, not ignored.

Will a corporate buyer pay the whole price at closing?

Usually not. Current corporate deals commonly pay 40% to 80% at close, averaging around 65%, with the rest in an earnout, seller note, JV interest, or parent-company equity.

Should I sell to my associate or to a consolidator?

An associate sale can preserve independence and culture but is limited by that individual's personal equity and lender-supported cash flow. A consolidator can pay a higher EBITDA multiple but usually requires an employment agreement, retention terms, and deferred or rollover value. Compare after-tax, risk-adjusted proceeds, not just the headline number.

Can a non-veterinarian buy a veterinary practice?

It depends on the state. Some states allow corporate ownership outright; others, like Texas, restrict the clinical entity to veterinarian owners. In restricted states, deals are commonly structured with a veterinarian-owned professional entity separate from a nonclinical management company, reviewed by state veterinary counsel.

Outside the US

UK vet practice sales run through a different regulatory frame (RCVS oversight rather than state boards) and have seen similarly heavy consolidation activity from groups such as IVC Evidensia and CVS Group. Australian practice sales follow state-based veterinary board rules and a smaller, more concentrated buyer pool. If your practice sits outside the US, the buyer logic and multiple bands above are directional at best; talk to an advisor who works in your specific market.

If you're weighing a sale or just want a realistic read on what your practice would fetch from the buyers actually active right now, we can walk through it with you, in confidence, before you talk to anyone else. Start a confidential conversation with Palmstone Capital.

Palmstone Capital Research